학술논문
Propranolol in the treatment of infantile haemangiomas: Lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce Survey.
Document Type
Author
Wedgeworth, E; Glover, M; Irvine, A D; Neri, I; Baselga Torres, E; Clayton, T H; Beattie, P E; Bjerre, J V; Burrows, N P; Foelster-Holst, R; Hedelund, L; Hernandez-Martin, A; Audrain, H; Bhate, K; Brown, S J; Baryschpolec, S; Darne, S; Durack, A; Dvorakova, V; Gach, J; Goldstraw, N; Goodyear, H; Grabcyznska, S; Greenblatt, D; Halpern, J; Hearn, R M R; Hoey, S; Hughes, B; Jayaraj, R; Johansson, E K; Lam, M; Leech, S; O'Regan, G M; Morrison, D; Porter, W; Ramesh, R; Schill, T; Shaw, L; Taylor, A E M; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Janmohamed, S R; Laguda, B; McPherson, T; Oranje, A; Patrizi, A; Ravenscroft, J; Shahidullah, H; Soloman, L; Svensson, Åke; Wahlgren, C F; Hoeger, P H; Flohr, C
Source
British Journal of Dermatology.
Subject
Language
English
ISSN
1365-2133
Abstract
Oral propranolol is widely prescribed as first line treatment for infantile haemangiomas (IHs) and anecdotally prescribing practice differs widely between centres.